Sep 4, 2025 | News
The Tribal Biotechnology & Health Consortium today filed its formal comment on the proposed CY 2026 Hospital Outpatient Prospective Payment System and Ambulatory Surgical Center Payment System rule (CMS-1834-P), addressing the proposed treatment of skin substitute...
Jul 25, 2025 | News
Clear Health Pass Holdings, on behalf of the Tribal Biotechnology & Health Consortium, today announced the appointment of David Burke, MD, MA as Principal Investigator for the post-market clinical validation of Rampart™ DL Matrix (Q4347). Dr. Burke is...
Jul 16, 2025 | News
The Tribal Biotechnology & Health Consortium today filed a 910-page substantive comment with the Centers for Medicare & Medicaid Services on the proposed CY 2026 Medicare Physician Fee Schedule. The filing, docketed at Regulations.gov as Comment ID...
Jun 12, 2025 | News
The Tribal Consortium’s Authorized Tribal Agent, Clear Health Pass Holdings, joined a working session with CMS Drug Pricing and the Coverage and Analysis Group to address the Average Sales Price submission and HCPCS code record for Rampart™ DL Matrix (Q4347)....
May 22, 2025 | News
The Centers for Medicare & Medicaid Services convened a formal Tribal Consultative Meeting with Clear Health Pass Holdings, Authorized Tribal Agent for the Tribal Biotechnology & Health Consortium, to review the federal coverage and reimbursement framework for...
